SCHEMBL408183

SCHEMBL408183

Cc1coc(C)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formamide SCHEMBL16742780 0.85 ENPP3 (0.35)
Formamide SCHEMBL21590223 0.83 ENPP3 (0.34)
SCHEMBL8829476 0.73 HSD17B10 (0.43)
SCHEMBL9911978 0.71 PTGS2 (0.40)
SCHEMBL7287721 0.71
SCHEMBL428940 0.71
SCHEMBL3579859 0.71
SCHEMBL111072 0.71
SCHEMBL5545210 0.71
SCHEMBL7041522 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 990 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11591300-B2 Oxazole containing compounds as activators of IDO1 and AhR THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2023-02-28 US claimed
CN-111293291-B Novel efficient lithium-sulfur battery positive electrode material and preparation method thereof 肇庆市华师大光电产业研究院 2022-04-26 CN claimed
US-20210009535-A1 OXAZOLE CONTAINING COMPOUNDS AS ACTIVATORS OF IDO1 AND AHR THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2021-01-14 US claimed
CN-111293291-A Novel efficient lithium-sulfur battery positive electrode material and preparation method thereof 肇庆市华师大光电产业研究院 2020-06-16 CN claimed
EP-2734516-B1 ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE BOEHRINGER INGELHEIM INT (DE) 2015-06-17 EP claimed
CN-103880861-A 4,6-dimethyl-oxazolo[5,4-d]pyrimidine-5,7(4H,6H)-dione derivative acting on FGF receptor UNIV WENZHOU MEDICAL 2014-06-25 CN claimed
EP-2025670-A1 3-(Phenyl or quinolyl)thio-1H-indole-1-acetic acid derivatives as modulators of CRTh2 receptor activity AstraZeneca AB (SE) 2009-02-18 EP claimed
US-20070249648-A1 Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases ASTRAZENECA AB (SE) 2007-10-25 US claimed
JP-2007509141-A 2007-04-12 JP claimed
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO claimed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US claimed
EP-1678178-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES AstraZeneca AB (SE) 2006-07-12 EP claimed
WO-2005040167-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2005-05-06 WO claimed
EP-4731622-A1 COMPOUNDS AND COMPOSITIONS AS VHL LIGANDS AND STAT3 DEGRADERS USES THEREOF Regents of the University of Michigan (US) 2026-04-29 EP disclosed
US-20260108613-A1 Compounds and Compositions as VHL Ligands and STAT3 Degraders Uses Thereof UNIV MICHIGAN (US) 2026-04-23 US disclosed
US-20250295713-A1 COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES DERMBIONT, INC. 2025-09-25 US disclosed
EP-0014402-A1 Novel 20-0-acylmaytansinoids, process for their preparation and pharmaceutical compositions containing them Takeda Chemical Industries, Ltd. (JP) 1980-08-20 EP disclosed
EP-0011302-A1 Maytansinoids, their production and use Takeda Chemical Industries, Ltd. (JP) 1980-05-28 EP disclosed
EP-0004466-A1 Demethyl maytansinoids and methods for producing them Takeda Chemical Industries, Ltd. (JP) 1979-10-03 EP disclosed
US-3961952-A ELECTROPHOTOGRAPHY, SUPPORTS, COATINGS ITEK CORPORATION (US) 1976-06-08 US disclosed